-+ 0.00%
-+ 0.00%
-+ 0.00%

The European Commission Approves 2mg/kg Every-4-weeks Dosing Regimen For Chiesi And Protalix Biotherapeutics' Elfabrio (Pegunigalsidase Alfa) For Fabry Disease Patients Who Are Stable With An Enzyme Replacement Therapy

Benzinga·03/09/2026 10:05:45
Listen to the news
  • European Commission approved dosing regimen reduces the burden for eligible patients, their families, and the broader healthcare system by extending infusion interval frequency from every-two-weeks to every-four-weeks for those stable with an enzyme replacement therapy (ERT)
  • With this decision, announced ahead of Fabry Disease Awareness Month in April, Chiesi Global Rare Diseases will work with countries across the EU to support broader access to this additional dosing schedule for the adult Fabry community